The UK medicines regulator has given approval for an experimental vaccine to be tested on healthy adults.
The small Ugandan city of Masaka is known mostly for its coffee, grown on rich volcanic soils that produce beans which have a ...
ATTR-CM treatment options narrowed after AstraZeneca and Ionis revealed their gene-silencing drug Wainua (eplontersen) failed ...
Health Minister Budi Gunadi Sadikin sets a target for Indonesia to domestically manufacture all 15 vaccine antigens used in ...
MRK trades above its 50- and 200-day SMAs as pipeline progress, acquisitions and Keytruda strength offset patent and vaccine ...
Unexpectedly catapulted into global fame as a COVID-19 vaccine maker, BioNTech is on the verge of returning to its oncology ...
Building on recent successes, scientists are focused on a promising new frontier: sending tiny particles into the body to ...
Samsung Biologics and Fujifilm Biotechnologies discuss how regional manufacturing, dual sourcing and networked CDMO capacity ...
2don MSN
AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.
By Raechel Thankam Job July 9 (Reuters) - AstraZeneca's nerve disease drug Wainua, made in partnership with Ionis, ...
Shares of AstraZeneca fell as much as 9% after a late-stage clinical trial for a heart disease drug failed to meet its target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results